Optimizing Breast Cancer Management

Buch | Softcover

V, 189 Seiten

2019 | 1. Softcover reprint of the original 1st ed. 2018
Springer International Publishing (Verlag)
978-3-319-88901-6 (ISBN)

Artikel merken

This book presents expert opinions on a variety of key topics related to the management of breast cancer, with a focus on the implications of recent advances and research findings for clinical practice. It also explores the controversy regarding mammography screening and reviews the contribution of new imaging modalities. Considerable attention is paid to developments in surgical procedures, including the potential for the safe and effective use of sentinel lymph node dissection alone-even in patients with positive nodes-and to the advantages and contraindications of new radiotherapy techniques. Genetic aspects are discussed in detail, including an assessment of the role of genetic testing and the potential impact of genetic signatures on breast cancer management. New systemic strategies, such as anti-HER2 therapy, endocrine agents, and agents to reverse endocrine resistance, are considered, and the optimal use of chemotherapy for early-stage and advanced-stage disease is addressed. Inclosing, the book shares important new insights into lifestyle risk factors, risk reduction strategies, and survivor issues, including sexual dysfunction and fertility maintenance.

Strategies to maintain fertility in young breast cancer patients.- Sexual dysfuncton in breast cancer survivors.- The breast cancer screening conundrum.- New Imaging modalities in breast cancer.- Is DCIS over treated.- "Personalizing" Breast Radiation.- Management of the axilla in early stage breast cancer.- Management of the breast in denovo MBC.- Identification of genetic lesions in patients with strong family history and no BRCA Mutation.- Managing "testing expectations" in breast cancer survivors.- The role of bone strengthening agents in early and advanced disease.- Overcoming endocrine resistance.- Optimal Adjuvant endocrine therapy.- Choosing wisely in HER2 positive metastatic breast cancer.- Should early stage, triple negative breast cancer be treated with preoperative systemic therapy?

Erscheinungsdatum	09.02.2019
Reihe/Serie	Cancer Treatment and Research
Zusatzinfo	V, 189 p. 11 illus. in color.
Verlagsort	Cham
Sprache	englisch
Maße	155 x 235 mm
Gewicht	305 g
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Gynäkologie / Geburtshilfe
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Radiologie / Bildgebende Verfahren
Schlagworte	Anti - HER2 Therapy • Bisphosphonates • Endocrine Resistance • Non-invasive Breast Cancer • Radiaton Oncology • Sentinel Lymph Node Dissection • triple negative breast cancer
ISBN-10	3-319-88901-X / 331988901X
ISBN-13	978-3-319-88901-6 / 9783319889016
Zustand	Neuware